S-1: Liminatus Pharma Goes Public via SPAC Merger, Faces Significant Financial Hurdles Despite Promising Cancer Therapy

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, has completed its business combination with Iris Acquisition Corp., listing on Nasdaq, but faces substantial doubt about its ability to continue as a going concern due to a history of significant losses and limited cash reserves.

Summary

• Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) completed its business combination with Liminatus Pharma, LLC on April 30, 2025, and its common stock and public warrants began trading on Nasdaq under symbols LIMN and LIMNW, respectively, on May 1, 2025.
• The company is a pre-clinical stage, pre-revenue biopharmaceutical firm focused on developing a next-generation CD47 immune checkpoint inhibitor (IBA101) for advanced solid cancers, including non-small cell lung cancer (NSCLC).
• Liminatus has incurred significant operating losses since inception, with a net loss of $3.5 million for the year ended December 31, 2024, and an accumulated deficit of $29.0 million as of March 31, 2025.
• As of March 31, 2025, the company had approximately $35 thousand in cash, and management believes current funds will not be sufficient to cover operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company's previous CAR-T and Vaccine License agreements with Targeted Diagnostics & Therapeutics, Inc. (TDT) were terminated in August 2024, and Liminatus is currently negotiating a $2.2 million amount due to TDT related to these terminated licenses.
• The business combination involved the issuance of 17.5 million shares of ParentCo Common Stock (deemed value $10.00/share) to Liminatus securityholders and a PIPE Equity Investment of $15.0 million from an accredited investor for 1.5 million shares at $10.00/share.
• Selling securityholders are registering for resale up to 21,154,961 shares of common stock, representing approximately 78.1% of total outstanding shares, which could lead to significant market price decline due to potential sales and lack of liquidity.
• The company may receive up to $79.35 million from the exercise of public warrants and $9.6089 million from private warrants, but cash proceeds are uncertain due to stock price volatility and low liquidity.
• Key preclinical studies for the CD47 asset, including CMC development and monkey toxicity studies, have been completed, with no significant IBA101-related effects noted at the highest dose (100 mg/kg/dose), indicating a No Observed Adverse Effect Level (NOAEL) at this dose.
• The CD47 antibody (Hu3A5) has shown preferential binding to immune cells over red blood cells and platelets, avoiding hemolysis, a common side effect of first-generation CD47 inhibitors like Magrolimab.
• Preclinical in vivo studies demonstrated complete tumor suppression when Hu3A5 was combined with an anti-PD1 antibody, and significant synergistic activity with other immune checkpoint inhibitors (anti-PD-L1, anti-TIGIT blocking antibodies, agonistic anti-4-1BB antibody).
• New potential therapeutic applications for the CD47 asset beyond cancer include reducing chronic inflammation and inducing weight loss, based on independent animal studies in high-fat diet mice.
• The company plans to file an Investigational New Drug (IND) application for IBA101, with a Phase 1 clinical trial for advanced solid cancers (initially lung cancer) scheduled for 2025, and a combination therapy trial (IBA101 + Durvalumab or Pembrolizumab) for stage III NSCLC in 2027.
• Liminatus will rely on third-party manufacturers for product candidates and third parties for clinical trials, reducing control over these activities.
• The company has identified a material weakness in its internal control over financial reporting as of December 31, 2024, related to a lack of formalized control environment, oversight, and segregation of duties.
• The company does not intend to pay cash dividends in the foreseeable future, with any return on investment expected from increases in stock price.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to severe financial distress, including a 'going concern' warning, a history of significant losses, and very limited cash. While the core product (CD47 inhibitor) shows promising preclinical differentiation and potential for broader indications, these scientific positives are heavily overshadowed by the company's precarious financial position, reliance on related-party debt, and the termination of previous key licenses. The high percentage of shares registered for resale also poses a significant dilution risk.

Positives

• Successful completion of a business combination and Nasdaq listing provides access to public markets for capital.
• The lead product candidate, IBA101 (CD47 immune checkpoint inhibitor), is a next-generation antibody designed to avoid red blood cell and platelet binding, addressing a key safety concern (anemia/thrombocytopenia) seen with first-generation inhibitors like Magrolimab.
• Key preclinical studies, including CMC development and monkey toxicity studies, have been completed for IBA101, showing a good safety profile with a No Observed Adverse Effect Level (NOAEL) at 100 mg/kg/dose.
• Preclinical in vivo studies demonstrate strong synergistic anti-tumor effects when IBA101 is combined with existing PD-1/PD-L1 blockades and other immune-oncology therapies, suggesting broad market potential.
• New potential indications for the CD47 asset beyond cancer, such as reducing chronic inflammation and inducing weight loss, were discovered in animal studies, expanding its therapeutic scope.
• A Phase 1 clinical trial for IBA101 in advanced solid cancers is scheduled for 2025, indicating progress towards human trials.
• The company has a strong leadership team with extensive global experience in the biopharma industry, covering all stages of development, commercialization, and financing.

Negatives

• Liminatus Pharma is a pre-clinical stage, pre-revenue company with a history of significant operating losses, including a net loss of $3.5 million in 2024 and an accumulated deficit of $29.0 million as of March 31, 2025.
• The company has limited cash reserves ($35 thousand as of March 31, 2025) and management has concluded there is substantial doubt about its ability to continue as a going concern for the next twelve months.
• Previous CAR-T and Vaccine License agreements with TDT were terminated in August 2024, indicating a reduction in the product pipeline and ongoing negotiations for a $2.2 million liability.
• The company is heavily reliant on third parties for clinical trials and manufacturing, which reduces control and introduces risks of delays or non-compliance.
• A material weakness in internal control over financial reporting was identified as of December 31, 2024, related to a lack of formalized control environment, oversight, and segregation of duties, which could impact financial reporting accuracy.
• Sales of a substantial amount of common stock by selling securityholders (approximately 78.1% of outstanding shares) could lead to a significant decline in the market price due to potential dilution and lack of liquidity.
• The company does not intend to pay cash dividends in the foreseeable future, meaning investor returns depend solely on stock price appreciation.

Risks

• Liminatus is a pre-clinical stage biotechnology company with a limited operating history and no products approved for commercial sale, making future success and viability difficult to predict.
• The company expects to continue incurring significant losses for the foreseeable future and may never achieve or maintain profitability.
• Liminatus will need substantial additional funds to advance development of its CD47 immune checkpoint inhibitor and cannot guarantee sufficient future funding, potentially forcing delays or elimination of development programs.
• Clinical development is a lengthy, expensive, and uncertain process, and results of earlier studies may not be predictive of future trial results, with a high risk of failure.
• The company has never successfully completed the regulatory approval process for any product candidates and may be unable to do so for its current or future candidates.
• Product candidates may have safety profiles that prevent regulatory approval, marketing acceptance, or limit commercial potential due to undesirable side effects or unexpected characteristics.
• If the company experiences delays or difficulties in patient enrollment for clinical trials, regulatory approvals could be delayed or prevented.
• Liminatus faces substantial competition from major pharmaceutical and biotechnology companies with significantly greater resources and experience.
• The company is highly dependent on its key personnel, and the inability to attract and retain qualified personnel could adversely affect its business strategy.
• Reliance on third parties (CROs, CMOs) for clinical trials and manufacturing increases risks of non-performance, delays, or supply chain issues.
• The business combination may be considered a change of control under certain intellectual property licenses, potentially leading to termination or reduced rights.
• Liminatus's proprietary rights may not adequately protect its intellectual property, and patents may be challenged, narrowed, or invalidated.
• Changes in patent law or interpretations could diminish the value of patents, impairing the ability to protect product candidates.
• Failure to comply with obligations in intellectual property license agreements could result in loss of development and commercialization rights.
• Third parties may allege infringement of their intellectual property rights, leading to costly litigation, injunctions, or substantial damages.
• The company's internal computer systems or those of third parties may suffer breakdowns, cyberattacks, or security breaches, compromising data and disrupting operations.
• Business disruptions from natural disasters, health crises, or geopolitical events (e.g., military action in Ukraine) could seriously harm operations and financial condition.
• The requirements of being a public company may strain resources, distract management, and incur substantial costs.
• Sales of a substantial amount of common stock by executive officers, directors, and significant stockholders, or the perception of such sales, could cause the market price to decline.
• If the company's shares become subject to 'penny stock' rules, it would become more difficult to trade them.
• The company is subject to extensive governmental regulations, and failure to comply with healthcare laws could lead to substantial penalties.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no guarantee of approval or timely approval.
• Product candidates may not achieve adequate market acceptance among physicians, patients, and payors, even if approved.
• The sizes of target patient populations may be inaccurate or smaller than estimated, limiting commercial potential.
• Product candidates may become subject to unfavorable third-party reimbursement practices and pricing regulations, impacting revenue and profitability.

Future Outlook

Liminatus Pharma, Inc. expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it advances its CD47 immune checkpoint inhibitor (IBA101) through clinical trials and seeks regulatory approval. The company anticipates needing substantial additional funding beyond the proceeds from the business combination to complete product development and potential commercialization. Future plans include initiating a Phase 1 clinical trial for IBA101 in advanced solid cancers in 2025, followed by a combination therapy trial in 2027, and actively evaluating additional assets for in-licensing or partnership to broaden its portfolio. The company aims to strengthen the differentiation of its anti-CD47 monoclonal antibody and build a leading immuno-oncology company.

Management Comments

• "Our vision is to develop transformative therapies for cancer patients as a global biopharmaceutical company offering advanced, differentiated, best-in-class therapies that induce powerful and durable responses in patients resulting in quality survival and a chance for cure."
• "We intend to do this through establishing a leadership position in immune-oncology and by strengthening the differentiation of the next generation anti-CD47 monoclonal antibody from IND enabling studies through to clinical development and broadening the portfolio through in-licensing highly promising and differentiated therapeutic assets."
• "We believe that our leadership teams extensive global experience within the biopharma industry, which spans all stages of development, commercialization and financing of pharmaceutical products, is a key competitive advantage for Liminatus in maximizing the full potential value of its pipeline."
• "The next generation of anti CD47 monoclonal antibodies have catalysed a resurgence of interest in the field."
• "Our CD47 program has been designed specifically to avoid RBC binding and prevent anemia, a common side effect seen with first-generation CD47 inhibitors. This key advantage has been initially demonstrated through in vitro experiments using human blood and in vivo toxicity studies in monkeys, further supporting its safety profile."
• "The strong results from our preclinical in vivo studies show that when our CD47 antibody is combined not only with already marketed PD-1/PD-L1 blockades but also with T cell boosters like LAG-3, TIGIT, TIM-3, and ICOS blockades, which are currently in active clinical development, it demonstrates a powerful synergistic effect. This versatility suggests significant market expansion potential as it could enhance the efficacy of various immune checkpoint inhibitors across multiple indications."
• "We are actively engaged in evaluating additional assets for in-licensing or partnership and may execute additional transactions to add to our pipeline. We believe that our leadership team has a proven track record for identifying and transacting upon de-risked clinical stage assets."

Industry Context

Liminatus Pharma operates in the highly competitive biotechnology and oncology sectors, specifically targeting immune-oncology with its next-generation CD47 immune checkpoint inhibitor. The global market for PD-1/PD-L1 blockades, a related area, was estimated at $49.5 billion in 2023 and is projected to reach $123.3 billion by 2033. Liminatus aims to penetrate this market primarily through combination therapy with established PD-1/PD-L1 blockades. The company's focus on a CD47 inhibitor positions it in a field that has seen renewed interest despite previous setbacks. For instance, Forty Seven Inc., a pioneer in CD47 research, was acquired by Gilead Sciences for $4.9 billion in 2020, but its lead candidate, Magrolimab, faced significant clinical trial setbacks due to efficacy and safety concerns, particularly anemia caused by red blood cell binding. Liminatus seeks to differentiate itself by developing a CD47 antibody that preferentially binds to immune cells but not red blood cells, potentially avoiding these severe side effects. The shift by Dr. Irving Weissman, a key figure in CD47 research, to explore CD47 blockers for cardiovascular diseases (via Bitterroot in 2023) aligns with Liminatus's own preclinical findings of broader applications beyond cancer, such as reducing chronic inflammation and inducing weight loss, suggesting a wider potential market for CD47-targeting therapies.

Comparison to Industry Standards

• **CD47 Target Differentiation:** Liminatus's CD47 antibody (Hu3A5) is designed to preferentially bind to immune cells, not red blood cells (RBCs) or platelets, a key differentiating feature from first-generation CD47 inhibitors like Magrolimab (developed by Forty Seven, acquired by Gilead Sciences). This aims to avoid common side effects such as anemia and thrombocytopenia that significantly hampered Magrolimab's clinical development, leading to termination of its Phase 3 trials (ENHANCE-3, ENHANCE, ENHANCE-2) and partial clinical holds on solid tumor studies.
• **Preclinical Efficacy:** In animal tumor models (MC38 murine colon adenocarcinoma cells expressing human CD47), Hu3A5 completely suppressed tumors in combination with an anti-PD1 antibody. This synergistic effect with established immune checkpoint inhibitors (like PD-1/PD-L1 blockades) and other T-cell boosters (LAG-3, TIGIT, TIM-3, ICOS blockades) suggests a versatile and potentially more effective approach compared to standalone treatments or less synergistic combinations seen in the industry.
• **Safety Profile (Preclinical):** The 4-week toxicity study in Cynomolgus monkeys for IBA101 (anti-CD47 mAb) showed no significant drug-related effects at the highest dose (100 mg/kg/dose), establishing a No Observed Adverse Effect Level (NOAEL) at this dose. This contrasts favorably with the safety issues (e.g., anemia) that plagued Magrolimab, indicating a potentially safer profile for Liminatus's candidate in early development.
• **Expanded Indications:** Liminatus's preclinical findings suggesting potential applications in reducing chronic inflammation and inducing weight loss (demonstrated in high-fat diet mice) expand the potential market beyond oncology. This aligns with the industry trend of exploring broader applications for immune-modulating therapies, as exemplified by Dr. Irving Weissman's new venture, Bitterroot, focusing on CD47 blockers for cardiovascular diseases, indicating a recognized, unmet need in these areas.
• **Development Stage:** Liminatus is a pre-clinical stage company, which is earlier than many competitors with candidates already in Phase 1, 2, or 3 trials. This implies higher risk and longer timelines to market compared to more advanced programs, but also potentially greater upside if successful.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings and is not aware of any pending or threatened claims as of March 31, 2025 and December 31, 2024.
• The company is engaged in negotiations with TDT regarding $2.2 million due to TDT following the termination of the CAR-T License and Vaccine License, with no agreement reached as of March 31, 2025.

Related Party Transactions

• **Business Combination:** Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) completed a business combination with Liminatus Pharma, LLC. Chris Kim, CEO of Liminatus Pharma, LLC, is also the CEO and controlling member of Valetudo Therapeutics LLC, a related party.
• **PIPE Equity Investment:** The PIPE Investor, Ewon Comfortech Co., Ltd., is a related party and shareholder, committing to purchase 1,500,000 shares for $15,000,000.
• **Founder Shares:** Iris Acquisition Holdings LLC (the Sponsor), a related party, paid $25,000 for 6,900,000 Founder Shares (Class B Common Stock, later converted to Class A) prior to the IPO.
• **Private Warrants:** The Sponsor and Cantor Fitzgerald & Co. (Cantor) purchased 5,013,333 Private Warrants for $7,520,000. The Sponsor forfeited 4,177,778 Private Warrants upon Business Combination closing.
• **Deferred Underwriting Fees:** Up to 1,750,000 shares of Common Stock are issuable to Cantor in settlement of $7.0 million in deferred underwriting fees.
• **Promissory Notes Related Party (Iris):** Iris had outstanding promissory notes totaling $1,453,720 as of March 31, 2025, from the Sponsor for working capital, which were non-interest bearing and due on demand. A previous 150% premium upon business combination was eliminated.
• **Administrative Support Agreement:** Iris entered into an agreement with Arrow Capital Management LLC (Arrow), a related party, for administrative support, incurring $90,000 for the three months ended March 31, 2025.
• **Loan Receivable (Liminatus to Iris):** Liminatus loaned Iris up to $5.0 million via an unsecured promissory note, with an outstanding balance of $4,243,500 as of March 31, 2025. This note was netted upon consolidation post-merger.
• **Feelux Bonds:** Liminatus issued $10.0 million of bonds to Feelux Co., Ltd., a shareholder and parent company of Car-Tcellkor, Inc., bearing 1% interest, with a carrying amount of $10.0 million as of March 31, 2025. Repayment has been deferred.
• **Car-Tcellkor Loan:** Liminatus borrowed $0.8 million from Car-Tcellkor, its former parent, with no interest, due May 18, 2023. Repayment has been deferred.
• **Valetudo Loans:** Liminatus borrowed $2.8 million from Valetudo Therapeutics LLC, a related party, through various loans with varying interest rates (0% to 6%) and maturity dates (mostly past due). Repayment has been deferred.
• **Ewon Loans:** Liminatus borrowed $3.2 million from Ewon Comfortech Co., Ltd., a member and related party, through various loans with varying interest rates (0% to 2%) and maturity dates (mostly past due). Repayment has been deferred.
• **Prophase Loans:** Liminatus borrowed $2.0 million from Prophase Sciences LLC, a related party, through various loans with 6% interest, mostly past due. An additional $3.6 million was borrowed in April 2025, with $3.4 million converted into private investment funds post-merger. Repayment of past due loans has been deferred.
• **Hana Loans:** Liminatus borrowed $0.9 million from Hana Immunotherapeutics, LLC, a related party, with 6% interest, mostly past due. Repayment has been deferred.
• **Amantes Loans:** Liminatus borrowed $1.0 million from Amantes LLC, a related party, with 6% interest, mostly past due. Repayment has been deferred.
• **Due to CEO:** Liminatus has $0.2 million due to Chris Kim, its CEO, for compensation under his employment agreement.
• **Due from Viral Gene:** Liminatus has $0.1 million due from Viral Gene, Inc., a related party (common CEO), for a non-interest bearing loan and expenses paid on its behalf.

Stakeholder Impact

• **Shareholders:** Existing shareholders face significant dilution risk from the large number of shares registered for resale by selling securityholders (78.1% of outstanding shares). The 'going concern' warning and history of losses pose substantial risk to investment value. Future capital raises may further dilute ownership. However, if the CD47 product is successful, there is potential for significant upside.
• **Employees:** The company plans to grow its organization, including hiring additional managerial, operational, sales, marketing, financial, and scientific personnel, which could create new employment opportunities. However, the 'going concern' risk implies job insecurity if additional funding is not secured.
• **Customers (Future):** If the CD47 product candidates receive regulatory approval, cancer patients could benefit from new, potentially more effective and safer treatment options, especially given the differentiation from first-generation CD47 inhibitors.
• **Suppliers/Creditors:** The company's precarious financial position and reliance on deferred repayment of significant related-party debt indicate a high risk for creditors. Unpaid amounts to TDT ($2.2 million) highlight potential disputes with former partners.
• **Regulatory Bodies:** The company is subject to extensive regulatory scrutiny and compliance requirements. Failure to meet these could result in penalties, delays, or withdrawal of approvals, impacting public health and regulatory trust.

Next Steps

• Prepare the Investigational New Drug (IND) application for IBA101.
• Prioritize a pre-IND meeting with the FDA.
• Initiate a Phase 1 clinical trial for IBA101 (mono) in advanced solid cancers, focusing on lung cancer patients, scheduled for 2025.
• Conduct additional preclinical animal studies utilizing mouse lung cancer cell lines (e.g., LL/2 expressing human CD47) if requested by the FDA to evaluate efficacy in lung cancer models.
• Initiate a global Phase 1 clinical trial for IBA101 in combination with Durvalumab or Pembrolizumab for stage III NSCLC patients (both PD-L1High and PD-L1Low), scheduled for 2027.
• Negotiate a final agreement with TDT regarding the $2.2 million amount due following the termination of the CAR-T and Vaccine Licenses.
• Raise additional cash through equity and debt financings or other arrangements to fund operations, as current funds are insufficient.
• Continue to evaluate steps to remediate the identified material weakness in internal control over financial reporting.
• Maintain and expand the intellectual property portfolio, including filing new patent applications for future IP opportunities (commercial formulations, dosing regimens, combination therapies, manufacturing methods, biomarkers, new patient populations).
• Seek to selectively form collaborations and strategic alliances to expand capabilities, accelerate R&D, and aid commercialization.
• Actively evaluate additional assets for in-licensing or partnership to broaden the product portfolio.

Key Dates

Keywords

Biopharmaceutical, Oncology, CD47 Inhibitor, IBA101, Pre-clinical Stage, Cancer Therapy, Immuno-oncology, SPAC Merger, Nasdaq Listing, Drug Development, Clinical Trials, Intellectual Property, Going Concern, Biotech, Solid Cancers, Non-small Cell Lung Cancer, Monoclonal Antibody